Thrive Wealth Management LLC Sells 4,487 Shares of GSK plc (NYSE:GSK)

Thrive Wealth Management LLC trimmed its position in shares of GSK plc (NYSE:GSK) by 38.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,249 shares of the pharmaceutical company’s stock after selling 4,487 shares during the quarter. Thrive Wealth Management LLC’s holdings in GSK were worth $245,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. FMR LLC raised its position in shares of GSK by 8.3% in the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC raised its position in shares of GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC raised its position in shares of GSK by 14.3% in the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after purchasing an additional 51,378 shares during the last quarter. Cerity Partners LLC raised its position in shares of GSK by 61.8% in the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock valued at $17,728,000 after purchasing an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC raised its position in shares of GSK by 20.0% in the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after purchasing an additional 83,433 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GSK has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Monday, January 13th. Finally, Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Price Performance

Shares of NYSE GSK opened at $33.46 on Monday. The stock has a market capitalization of $69.34 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The firm’s 50 day simple moving average is $34.02 and its 200-day simple moving average is $37.98. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were paid a dividend of $0.3928 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date was Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.70%. GSK’s dividend payout ratio (DPR) is presently 96.10%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.